JOURNAL READING

Comparison of Pregabalin with Pramipexole

for Restless Legs Syndrome

Pembimbing : dr. Nushrotul

Lailiyya, SpS, SpAK
Presentan : dr.Frans Jobeth

Background
Moderate-to-severe restless legs syndrome

(RLS), now also known as WillisEkbom

disease, with its predominantly nocturnal,
rest-induced, distressing urge to move the
legs. Profoundly disrupts sleep, quality of
life, and daytime productivity and often
requires treatment for years.
Levodopa

and
short-acting
agonists
(pramipexole
and
relieve RLS symptoms

dopamine
ropinirole)

In

patients treated with dopamine

agonists, RLS can worsen over several
years (more pervasive and more intense
than they were before treatment).
The worsening of symptoms has been
assumed
to
be
iatrogenic,
an
augmentation of RLS severity that
occurs with dopaminergic treatment
rather than a natural progression of the
disease

Augmentation, unlike loss of efficacy,

produces RLS symptoms that are worse

than those occurring before treatment
(e.g., symptoms start earlier in the day,
are more intense, and extend to more
areas of the body).
Dose increases appear to exacerbate
augmentation

Method

Patients
Adults (age 18 years) with moderate-to-

severe primary RLS, diagnosed by study

investigators on the basis of the International
RLS (IRLS) Study Group criteria, were
screened for participation in the study.
Eligibility criteria included:
symptoms that occurred predominantly at night
symptom onset at least 6 months before

screening, and
the presence of symptoms on 15 or more nights
in the month before screening.

The score on the IRLS Study Group Rating

Scale had to be 15 or higher at the

beginning and end of a 1-week placebo
run-in period.
Patients with a prior clinical report of RLS

augmentation were excluded

Study Design
This randomized, active-comparator,

placebocontrolled, double-blind trial was

conducted at 102 sites in the United States
and Europe between December 2008 and
June 2011.

Study Treatments and

Procedures
Patients were randomly assigned to receive

placebo, 0.25 mg of pramipexole per day,

0.5 mg of pramipexole per day, or 300 mg
of pregabalin per day for 12 weeks in
capsules that were identical in appearance
after which patients receiving placebo were

randomly assigned to one of the three

active treatments for the remainder of the
study (an additional 40 weeks)

Placebo

0,25mg
Pramipexole
0,5mg
Pramipexole
300mg

12 Weeks

Pregabalin

0,25mg
Pramipexole
0,5mg
Pramipexole
300mg
Pregabalin

52 Weeks

Medication doses were increased over

the first 2 weeks of the study to the final

fixed dose.
The pregabalin dose was based on the
results of a prior dosefinding study
Medication was administered orally, 1 to
3 hours before bedtime. The use of
concomitant RLS medications was not
allowed.

Visits were scheduled at the start of

treatment and at 2, 6, 10, 12, and 14

weeks after the start of treatment
thereafter (until the end of the study, 52
weeks from the start of treatment), visits
were monthly.

At each visit, the patient, with an

investigator, completed:
The IRLS severity scale
The Augmentation Severity Rating Scale

(ASRS) (which ranges from 0 to 24, with a

score of 5 indicating mild augmentation and
higher scores indicating more severe
augmentation)
The Structured Interview for the Diagnosis of
Augmentation (SIDA) during RLS treatment

Identification of cases of possible

augmentation was based on clinical

judgment, a total ASRS score of 5 or higher,
or a positive SIDA score.

The study had three primary end points:

For the comparison of pregabalin with placebo
The change from baseline to week 12 in the IRLS

score and in the proportion of patients with a CGI-I

evaluation of much improved or very much
improved, and
For

the
comparison
of
pregabalin
with
pramipexole, the change from baseline to week
40 or week 52 in the percentage of participants
with augmentation

Key

secondary efficacy end points

included a comparison of the efficacy of
pregabalin and pramipexole over a
period
of
12
weeks
(short-term
comparison) and pramipexole over a
period of 40 or 52 weeks (long-term
comparison), as assessed with the use
of the IRLS scale.

Patient-reported measures included:

limb pain as assessed on a visual-analogue

scale
quality of life with RLS as assessed on a
questionnaire,and
sleep as assessed on a subjective sleep
these factors were evaluated during the first 12
weeks of the study.

Results

Study patients
Total of 731 patients underwent

randomization at 102 centers in the

United States and Europe;
719 received one or more doses of the
study drug

After 12 weeks, patients who received

pregabalin, as compared with those who

received placebo, had a significantly
greater reduction (improvement) in the
IRLS score
Greater proportion of patients in the
pregabalin group had symptoms that
were reported as very much or much
improved on the CGI-I evaluation (71.4%
vs. 46.8%, P<0.001)

As compared with placebo, the 0.5-mg dose

of pramipexole, but not the 0.25-mg dose,

was associated with a significant reduction
in the IRLS score and a significantly greater
proportion of patients with improvement on
the CGI-I evaluation

 Among the 235 patients receiving pregabalin (for 40

or 52 weeks), 5 (2.1%) had augmentation, as

compared with 12 of 225 patients receiving 0.25 mg
of pramipexole (5.3%, P = 0.08) and 18 of 235
patients receiving 0.5 mg per day (7.7%, P = 0.001)
Among patients receiving active treatment over the

entire 52-week study period, augmentation

occurred in 3 of 176 patients receiving pregabalin
(1.7%), 11 of 167 receiving 0.25 mg of pramipexole
(6.6%), and 16 of 178 receiving 0.5 mg of
pramipexole (9.0%)

Secondary Outcomes
Scores for limb pain and quality of life

improved from baseline scores with

pregabalin and with 0.5 mg of pramipexole
There was greater improvement in several

measures of sleep with pregabalin than

with either dose of pramipexole, including
waking after sleep onset, quality of sleep,
number of awakenings, and total sleep
time.

Adverse Events
The most common adverse events

were
dizziness,
somnolence,
fatigue,
and
headache, with pramipexole, the most
common events were headache, nausea,
and fatigue.

Adverse

events
leading
to
study
discontinuation, the most common events
were somnolence and dizziness with
pregabalin and nausea and headache with
pramipexole.

Discussion

Assessment of the studys primary end

points showed that 300 mg of

pregabalin per day, as compared with
placebo, significantly improved RLS
treatment outcomes after 12 weeks and
was associated with significantly less
augmentation than a dose of 0.5 mg of
pramipexole per day, but not a dose of
0.25 mg per day, after 52 weeks.

Evidence of four important aspects of RLS

augmentation:
1. RLS augmentation is an iatrogenic
worsening related to dopaminergic
medication, not a naturally occurring
worsening or a worsening resulting from
medical or behavioral factors.
2. Longer exposure to medication increases
augmentation rates

3. The incidence of augmentation was

greatest with the higher pramipexole dose.
4. The 52-week rate of augmentation
among patients receiving pramipexole in
our study is similar to the rates in two
long-term,
uncontrolled,
retrospective
studies (7%13 and 8%9), despite the use
of different methods and different patient
populations.

IRLS scores for patients receiving

pregabalin were significantly higher than

the scores for patients receiving 0.25 mg of
pramipexole
Treatment with pregabalin was not superior

to treatment with 0.5 mg of pramipexole.

THANK YOU

CGI-I guidelines
1 = Very much improvednearly all better; good level of functioning;
minimal symptoms; represents a very substantial change
2 = Much improvednotably better with significant reduction of
symptoms; increase in the level of functioning but some symptoms remain
3 = Minimally improvedslightly better with little or no clinically
meaningful reduction of symptoms. Represents very little change in basic
clinical status, level of care, or functional capacity
4 = No changesymptoms remain essentially unchanged
5 = Minimally worseslightly worse but may not be clinically meaningful;
may represent very little change in basic clinical status or functional
capacity
6 = Much worseclinically significant increase in symptoms and
diminished functioning
7 = Very much worsesevere exacerbation of symptoms and loss of
functioning

Statistical analysis
The CGI-I evaluation for the comparison of

pregabalin with placebo at week 12, with

the last observation carried forward, was
analyzed with the use of the Cochran
MantelHaenszel test, stratified according
to region (the United States or Europe).
Augmentation rates were analyzed by
means of a stratified log-rank test.

Restless legs syndrome (RLS) is a

neurological disorder characterized by

throbbing, pulling, creeping, or other
unpleasant sensations in the legs and an
uncontrollable, and sometimes
overwhelming, urge to move them.
Symptoms occur primarily at night when a
person is relaxing or at rest and can
increase in severity during the night.
Moving the legs relieves the discomfort.
Often called paresthesias (abnormal
sensations) or dysesthesias (unpleasant
abnormal sensations), the sensations range

Most people with RLS have difficulty falling

asleep and staying asleep. Left untreated,

the condition causes exhaustion and
daytime fatigue. Many people with RLS
report that their job, personal relations, and
activities of daily living are strongly
affected as a result of their sleep
deprivation.

In most cases, the cause of RLS is

unknown. However, it may have a genetic

component; RLS is often found in families
where the onset of symptoms is before age
40.
Specific gene variants have been
associated with RLS.
Evidence indicates that low levels of iron in
the brain also may be responsible for RLS.

RLS also appears to be related to the following factors or

conditions, although researchers do not yet know if these

factors actually cause RLS:
Chronic diseases such as kidney failure, diabetes, and

peripheral neuropathy. Treating the underlying condition often

provides relief from RLS symptoms.
Certain medications that may aggravate symptoms. These
medications include antinausea drugs (prochlorperazine or
metoclopramide), antipsychotic drugs (haloperidol or
phenothiazine derivatives), antidepressants that increase
serotonin, and some cold and allergy medications-that
contain sedating antihistamines.
Pregnancy, especially in the last trimester. In most cases,
symptoms usually disappear within 4 weeks after delivery.

The four basic criteria for diagnosing the disorder

are:
Symptoms that are worse at night and are absent or

negligible in the morning;

A strong and often overwhelming need or urge to
move the affected limb(s), often associated with
paresthesias or dysesthesias;
Sensory symptoms that are triggered by rest,
relaxation, or sleep; and
Sensory symptoms that are relieved with movement
and the relief persists as long as the movement
continues.

TREATMENT
Dopaminergic agents (drugs that increase

dopamine)
long-term use can lead to worsening of the symptoms in many
individuals. This apparent progressive worsening is referred to
as augmentation. With chronic use, a person may begin to
experience symptoms earlier in the evening than in the
afternoon until finally the symptoms are present around the
clock. The initial evening or bedtime dose becomes less
effective, the symptoms at night become more intense, and
symptoms begin to affect the arms or trunk.
Benzodiazepines

Opioids
Anticonvulsants

PRAMIPREXOLE
Dopamine agonist of the non-ergoline class

indicated for treating Parkinson's disease

(PD)[1] and restless legs syndrome (RLS)
Pramipexole acts as a partial/full agonist at
the following receptors:
D2S receptor (Ki = 3.9 nM; IA = 130%)
D2L receptor (Ki = 2.2 nM; IA = 70%)
D3 receptor (Ki = 0.5 nM; IA = 70%)
D4 receptor (Ki = 5.1 nM; IA = 42%)

Pregabalin
Pregabalin is structurally related to the

antiepileptic drug gabapentin and the site of

action of both drugs is similar, the alpha2delta (alpha2-delta) protein, an auxiliary
subunit of voltage-gated calcium channels.
Pregabalin subtly reduces the synaptic
release of several neurotransmitters,
apparently by binding to alpha2-delta
subunits, and possibly accounting for its
actions in vivo to reduce neuronal
excitability and seizures.

Several studies indicate that the

pharmacology of pregabalin requires

binding to alpha2-delta subunits, including
structure-activity analyses of compounds
binding to alpha2-delta subunits and
pharmacology in mice deficient in binding
at the alpha2-delta Type 1 protein.
The preclinical findings to date are
consistent with a mechanism that may
entail reduction of abnormal neuronal
excitability through reduced
neurotransmitter release.